Has Debopam Samanta received payments from drug or device companies?

Yes. Drug and device makers reported $21,276 in general payments to Debopam Samanta across 31 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Debopam Samanta did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Debopam Samanta come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Debopam Samanta

Neurology with Special Qualifications in Child Neurology · Little Rock, ARNPI 1336393784

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,222 of the $21,276 with a category attached, or 71.5%. 10 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 36.6% of the total. Reporting peaked in 2023 at $11,543 and has fallen 88.4% since, to $1,338 in 2025.

$21,276in general payments, 2019–2025

Across 31 payments — averaging $686.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$8K
Neurelis, Inc.$6K
H. Lundbeck A S$1K
Neuropace, Inc.$1K
Otter Pharmaceuticals, LLC$1K
Nobelpharma America, LLC$1K
plus $2K from 4 others

$370,739in research payments, 2019–2025

Across 76 payments — averaging $4878.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Immedica Pharma US, Inc.$226K
H. Lundbeck A S$122K
GW Research Limited$13K
Jazz Pharmaceuticals Inc.$10K

What the payments were for

Consulting fees$15,22272%
Speaking & faculty fees$1,2906%
Travel & lodging$3,76318%
Food & beverage$1,0015%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	4	$7,781
Neurelis, Inc.	11	$6,211
H. Lundbeck A S	4	$1,383
Neuropace, Inc.	6	$1,370
Otter Pharmaceuticals, LLC	1	$1,338
Nobelpharma America, LLC	1	$1,290
Zogenix Inc.	1	$1,100
Biogen	1	$550
Cadwell Industries, Inc	1	$150
Biocodex, Inc.	1	$103

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Epidiolex$7,781
VALTOCO$6,051
SYMPAZAN$1,338
HYFTOR$1,290
RNS Neurostimulator Kit$1,265
Fintepla$1,100
DIACOMIT$103

How this compares

Too few neurology with special qualifications in child neurology providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Other neurology with special qualifications in child neurology in Little Rock

Aravindhan VeerapandiyanLittle Rock$600K
Stephen JonesLittle Rock$200
Gregory SharpLittle Rock$59
Sarah CobbLittle Rock$38
William WaltersLittle Rock$19
Christopher ManbeckLittle Rock$19
Virginia WillisLittle Rock$14
Paul DrakeLittle Rock$0
Adrianne ParkeyLittle Rock$0
Tonya BalmakundLowell$1K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →